Multiple Myeloma

P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn

RT-qPCR validation confirmed a significant up- regulation of these six genes in MM. Six prognostic genes associated with CA in MM were identified, and a predictive risk model was developed, offering valuable insights for clinical prognosis and immunotherapy in MM.

P2, N=150, Recruiting, University Hospital, Clermont-Ferrand | Trial completion date: Dec 2027 --> May 2030 | Trial primary completion date: Oct 2026 --> May 2030

P=N/A, N=100, Not yet recruiting, PETHEMA Foundation

P1, N=20, Recruiting, The General Hospital of Western Theater Command | Not yet recruiting --> Recruiting

P3, N=390, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed

P=N/A, N=50, Not yet recruiting, Odense University Hospital

This indicates that although proteasomal inhibition is not inflammatory, TNF present in the microvascular environment synergizes with the drugs to compromise endothelial function. Our observations provide an explanation for how microvascular damage potentially underlies tissue injury driven by Bortezomib or Carfilzomib.

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

By developing and characterizing a unique RiboCancer cell line panel, we mapped translational rewiring driven by the most frequent somatic RP mutations. We provide unprecedented mechanistic insights into translation defects induced by CLL-associated Rps15 mutations, and reveal an intriguing translation-based rewiring of transcription in CLL.

The CD70-targeted theranostic pair allows precise imaging and effective radiotherapy in MM models. Low-dose [177Lu]Lu-DOTA-ABDB6 treatment (40-80 µCi) is safe and effective, supporting clinical translation. Future studies should explore repeated dosing or the use of alpha-emitters (eg, 225Ac) to improve durability. [89Zr]Zr-DFO-ABDB6/[177Lu]Lu-DOTA-ABDB6 theranostic pair provides a novel management strategy for CD70-positive MMs.

P1, N=165, Recruiting, K36 Therapeutics, Inc. | N=125 --> 165